Desiree van der Heijde
Overview
Explore the profile of Desiree van der Heijde including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
728
Citations
29839
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Pina Vegas L, van Lunteren M, Loeuille D, Morizot C, Newsum E, Ramiro S, et al.
Eur Radiol
. 2025 Mar;
PMID: 40050452
Objectives: To investigate the occurrence of spinal degenerative lesions (DL)s in axial spondyloarthritis (axSpA) inception cohort in radiographs and MRI over 10 years (10Y), to assess their changes over time...
2.
Poddubnyy D, Navarro-Compan V, Torgutalp M, Arends S, Aydin S, Battista S, et al.
Ann Rheum Dis
. 2025 Feb;
PMID: 39955166
Objectives: To develop a consensus-based expert definition of difficult-to-manage (D2M) axial spondyloarthritis (axSpA), incorporating treatment-refractory (TR) disease. Methods: A literature review was conducted in 2022 to identify potential definitions for...
3.
van der Heijde D, Navarro-Compan V, Landewe R, Sieper J, van Gaalen F, Gensler L, et al.
Ann Rheum Dis
. 2025 Feb;
84(3):382-387.
PMID: 39948004
Objective: To describe the role of the Assessment of SpondyloArthritis interntational Society (ASAS) over the past 30 years in the understanding of the field of spondyloarthritis. Methods: A narrative review...
4.
Van den Bosch F, Deodhar A, Poddubnyy D, Maksymowych W, van der Heijde D, Kim T, et al.
Arthritis Res Ther
. 2025 Feb;
27(1):23.
PMID: 39905436
Background: In SELECT-AXIS 2, upadacitinib improved the signs and symptoms of active non-radiographic axial spondyloarthritis (nr-axSpA) through 52 weeks versus placebo and was well tolerated. Here, we evaluated the efficacy...
5.
Deodhar A, Navarro-Compan V, Poddubnyy D, Gensler L, Ramiro S, Tomita T, et al.
RMD Open
. 2025 Jan;
11(1).
PMID: 39890205
Objective: Assess long-term safety, tolerability and efficacy of bimekizumab in ankylosing spondylitis (radiographic axial spondyloarthritis (r-axSpA)). Methods: Patients with active r-axSpA completing the dose-ranging 48-week randomised controlled trial could enrol...
6.
Perez-Alamino R, Maldonado-Ficco H, Molto A, Waimann C, Maldonado-Cocco J, Dougados M, et al.
RMD Open
. 2025 Jan;
11(1).
PMID: 39890204
Background: Diagnostic delay is one of the greatest challenges in spondyloarthritis (SpA). Better disease knowledge and more accessibility to new image technology could have a positive impact on time to...
7.
Calixto O, Kiltz U, Bautista-Molano W, Boonen A, van Kuijk S, Essers I, et al.
Rheumatology (Oxford)
. 2025 Jan;
PMID: 39878952
Objectives: To compare the utility values of Spondyloarthritis (SpA)-specific ASAS Health Index (U-ASAS-HI) to generic utilities and to understand the contribution of health outcomes, personal- and country-level factors to the...
8.
Baraliakos X, Deodhar A, van der Heijde D, Van den Bosch F, Magrey M, Maksymowych W, et al.
Rheumatology (Oxford)
. 2025 Jan;
PMID: 39798135
Objectives: Bimekizumab, a monoclonal IgG1 antibody that selectively inhibits interleukin (IL)‑17F in addition to IL-17A, previously demonstrated efficacy and was well tolerated to 1 year in patients with non-radiographic (nr-)...
9.
Capelusnik D, Nikiphorou E, Boonen A, Christensen R, van der Heijde D, Landewe R, et al.
RMD Open
. 2024 Dec;
10(4.
PMID: 39658054
Objectives: To compare the construct validity, including discrimination between known groups, of three pain and three morning stiffness (MS) measurement instruments. Methods: Patients with radiographic axial spondyloarthritis with 8-year data...
10.
Baraliakos X, van der Heijde D, Sieper J, Inman R, Kameda H, Maksymowych W, et al.
Arthritis Res Ther
. 2024 Nov;
26(1):197.
PMID: 39533349
Background: The efficacy and safety of upadacitinib in patients with ankylosing spondylitis (AS) and inadequate response/intolerance to biologic disease-modifying antirheumatic drugs (bDMARD-IR) were evaluated through 1 year in the SELECT-AXIS...